NASTAD Releases Key Findings of the 2014 National AIDS Drug Assistance Program (ADAP) Monitoring Project Annual Report

By Amanda Bowes, Associate, Health Care Access and Viral Hepatitis, NASTAD

2014 National ADAP Monitoring Project Annual ReportToday, the National Alliance of State and Territorial AIDS Directors (NASTAD) released key findings of the 2014 National ADAP Monitoring Project Annual Report. The National ADAP Monitoring Project is NASTAD’s long-standing effort to document new developments and challenges facing AIDS Drug Assistance Programs (ADAPs), assessing key trends over time and providing the latest available data on the status of ADAPs. For the last 19 years, NASTAD has provided comprehensive analysis about ADAPs through The Report.

The Report provides an overview of the status of ADAPs as they prepared for full implementation of the Affordable Care Act (ACA). Continue reading

After Five Years, ADAP Waiting Lists Have Been Eliminated

ADAP Watch No Waiting Lists November 2013After Five Years, ADAP Waiting Lists Have Been Eliminated; Unmet Need and Funding Uncertainties Require Continued Commitment

FOR IMMEDIATE RELEASE
Contact: Murray Penner
202-434-8090
mpenner@NASTAD.org

November 25, 2013, Washington, DC – According to NASTAD’s latest ADAP Watch, released today, there are no individuals on AIDS Drug Assistance Program (ADAP) waiting lists in the United States. This represents a significant milestone as there have been individuals on ADAP waiting lists since January 2008. The last state to have a waiting list, South Dakota, was able to transition the remaining 11 individuals on their waiting list into their ADAP program on November 21. Earlier this month, Alabama and Idaho eliminated their waiting lists and lifted their enrollment caps.  Continue reading

ADAP Crisis Task Force Announces Continued Partnership with Bristol-Myers Squibb and Boehringer Ingelheim for AIDS Drug Assistance Programs in the United States

FOR IMMEDIATE RELEASE
Contact: Murray Penner
202-434-8090
mpenner@NASTAD.org

ADAP AlertOctober 28, 2013, Washington, DC – The ADAP Crisis Task Force (Task Force) announced today that it has reached agreement with Bristol-Myers Squibb (BMS) and Boehringer Ingelheim (BI) to extend voluntary discounts/rebates and price freezes to all state AIDS Drug Assistance Programs (ADAPs).  The continuation of existing agreements beyond 2013 will provide stability to ADAPs as they continue to navigate the uncharted terrain of a reformed health system as a result of implementation of the Affordable Care Act (ACA) and continued fiscal challenges at both the state and federal level.

The Task Force, convened by the National Alliance of State and Territorial AIDS Directors (NASTAD), previously secured continuation through 2014 of existing agreements for voluntary discounts and rebates from AbbVie, Gilead Sciences, Janssen Therapeutics, Merck and ViiV Healthcare.  Many of these agreements also provide continued price freezes for ADAPs for varying lengths of time into 2014 and 2015.  Continue reading

ADAP Crisis Task Force Announces Agreement with ViiV Healthcare for Tivicay®

FOR IMMEDIATE RELEASE
Contact: Meico Whitlock
202-434-8090

ADAP Crisis Task Force Announces Agreement with ViiV Healthcare for TivicayAugust 26, 2013, Washington, DC – The ADAP Crisis Task Force (ACTF) has reached a new pricing agreement with ViiV Healthcare for AIDS Drug Assistance Programs (ADAPs) for Tivicay® (dolutegravir) for the treatment of HIV-1 infected individuals. The agreed-upon ADAP direct purchase price for Tivicay®, negotiated between the ACTF and ViiV, is substantially lower than the wholesale acquisition cost (WAC), reflecting voluntary discounts that are also significantly below the mandated 340B pricing of the medication.

Continue reading

ADAP Crisis Task Force Announces Agreement with Industry Partners

FOR IMMEDIATE RELEASE
Contact: Murray Penner
202-434-8090
mpenner@NASTAD.org

ADAP Crisis Task ForceJuly 29, 2013, Washington, DC – As part of ongoing efforts by the ADAP Crisis Task Force (Task Force) and the pharmaceutical industry to address the continued need for access to HIV antiretroviral medicines through AIDS Drug Assistance Programs (ADAPs), the Task Force announced today that it has reached agreement with AbbVie, Gilead Sciences, Merck, and ViiV Healthcare to extend the voluntary discounts/rebates and price freezes available to all state ADAPs through December 31, 2014.

Continue reading